Kevin's Watch

Researchers have revealed a proof of principle clinical trial that used a high dose 'blast' of a specially engineered version of the measles virus to cure cancer.

Two patients underwent the treatment, which researchers stress was at the earliest stage of human trials.

Both patients responded, showing reduction of both bone marrow cancer and myeloma protein, with one, a 49-year-old woman, experiencing complete remission of myeloma - and has been clear of the disease for over six months.

In layman's terms: "It puts the virus into bloodstream, it infects and destroys the cancer, debulks it, and then the immune system can come and mop up the residue." Up next: larger-scale studies, and tests of the vaccine's effectiveness against ovarian, brain, head, and neck cancers, as well as mesothelioma.